Overview

Corporate Presentation

Corporate Presentation - May 2021

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Jun 9, 2021

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to...

May 13, 2021

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to...

May 6, 2021

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to...

View All Press Releases

Events
Wednesday, June 16, 2021
9:00am EDT

View All Events

We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Explore Our Pipeline